Back to search

University of Crete (UOC)

Βιοχημική και ανοσολογική μελέτη της δράσης των αυξητικών παραγόντων στη βιοσύνθεση εκκρινόμενων Chondroitin και Dermatan sulfate πρωτεογλυκανών σε κυτταρικές σειρές μελανώματος και φυσιολογικών μελανοκυττάρων

Abstract

dc:description

Melanoma is a frequent and therapy resistant human malignancy with a rising incidence rate, worldwide (Houghton et al., 2002). Malignant melanoma arises in the epidermis either in situ or in an invasive form, progressing from radial growth phase to vertical growth phase through enhanced invasion into the dermis (Lever, 2005). With malignant progression tumor cells partly through autocrine and paracrine production of growth factors and cytokines actively modulate their microenvironment in a tumor-favourable way to enable successful invasion (Selvamurugan et al., 2002; Hakamori et al., 2002; Nikitovic et al., 2006). The dermis extracellular matrix (ECM) consists of different types of collagens, glycoproteins, hyaluronan (HA) and proteoglycans (PGs) (Wang et al., 2003). Members of the small leucine-rich proteoglycans (SLRPs) family were found to participate in both the structural and the functional organization of the skin (Wang et al., 2003; Carrino et al., 2000). Previously it was shown that the SLRP lumican significantly affects the mechanical properties of the skin and that the lack of its expression results in skin fragility and laxity (Carrino et al., 2000; Vuillermoz et al., 2005). The role of lumican has been investigated in the growth and metastasis of several cancers, without being fully elucidated (Naito, 2005). Specifically it was demonstrated that human colorectal cancer cells (Lu et al., 2002), cervical squamous carcinoma cells (Naito, 2002) and pancreatic adenocarcinoma cells express lumican mRNA and different glycosylated types of its protein (Lu, 2002). In contrast, lumican in breast cancer tissues is expressed in fibroblasts adjacent to cancer cells but not in cancer cells (Leygue et al., 1998). Furthermore, it has been demonstrated that reduced expression of lumican is associated with poor outcome in node-negative invasive 6 breast cancer (Troup et al., 2003) while high expression level of lumican is associated with a high pathological tumor grade, low estrogen receptor levels in the cancer tissue, and younger age of patients (Leygue et al., 1998). Pancreatic myofibroblasts of the tumor stroma were also found to strongly overexpress lumican (Koninger et al., 2004). An in vitro/in vivo study showed that lumican expression by transfected B16F1 mouse melanoma cells resulted in inhibition of hypodermal melanoma growth in syngenic mice, but failed to change the B16F1 cell differentiation, growth rate and adhesion properties (Vuillermoz et al2004). The above reports suggest that lumican may have a role both in the host reaction of the peritumoral cells as well as in tumor growth. The expression of lumican by human melanoma cells has not, to our knowledge, been reported. The aim of the present study was to investigate and to characterize lumican expression at the mRNA, protein and carbohydrate level, in two human malignant melanoma cell lines (WM9 and M5) and normal neonatal human melanocytes (HEMN). Both human metastatic melanoma cell lines were found to express lumican mRNA and effectively secrete lumican in a proteoglycan (PGs) form, characterized to be substituted mostly with keratan sulfate chains. Lumican mRNA was not detected in normal melanocytes. This is the first time that the synthesis and secretion of lumican in human melanoma cell lines is reported. The role of this proteoglycan in the development and progression of malignant melanoma has to be further investigated. The members of the fibroblast growth factor (FGF) family (Eswarakumar, Lax, & Schlessinger, 2005) function through four distinct, high-affinity cell surface receptors with intrinsic tyrosine kinase activity, designated FGFR1–4 (Basilico & Moscatelli, 1992). The binding of FGFs to the extracellular ligand domain of FGFRs induces receptor dimerization, activation and autophosphorylation of multiple 7 tyrosine residues in the cytoplasmic domain of the receptor molecule (Jaye, Schlessinger, & Dionne, 1992), leading to the stimulation of intracellular signaling pathways that control cell proliferation, differentiation, migration or survival (Eswarakumar et al., 2005). Human melanomas most uniformly constitutively express basic fibroblast growth factor (FGF-2). As these cancer cells simultaneously express FGFRs their growth is stimulated by FGF-2 in an autocrine manner (Rodeck, 1993; Rodeck et al., 1991; Yeoman, 1993). The biological significance of this autocrine loop has been demonstrated using anti-sense oligonucleotides that targeted FGF-2 or by inactivating FGF-2 with anti-FGF-2 antibodies resulting in an inhibition of melanoma cell proliferation both in vitro and in vivo (Beckcer, Meier, & Herlyn 1989; Rofstad & Halsor, 2000; Wang & Becker, 1997). On the other hand, increased expression of FGF-2 stimulates the transformed melanoma phenotype demonstrating that FGF-2-dependent signaling is essential in melanoma tumor progression (Meier et al., 2000)...

Degree

thesis:*
Grantor dc:publisher
University of Crete (UOC)
Year dc:date
2009

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Sifaki, Maria
  • Σηφάκη, Μαρία

Subjects

dc:subject × 15

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/24967

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Sifaki, Maria; Σηφάκη, Μαρία. Βιοχημική και ανοσολογική μελέτη της δράσης των αυξητικών παραγόντων στη βιοσύνθεση εκκρινόμενων Chondroitin και Dermatan sulfate πρωτεογλυκανών σε κυτταρικές σειρές μελανώματος και φυσιολογικών μελανοκυττάρων. University of Crete (UOC), 2009. http://hdl.handle.net/10442/hedi/24967